After ImCheck’s inception in 2015, Pierre took the helm through clinical development and guided the startup to a $1.2B buyout by Ipsen in 2025.
In a session at the Kadans Oncology Summit, he talks about how the exit materialised and the oncology space, including highlights from ASCO 2026, ADCs, in vivo CAR-T & checkpoint inhibitors.
He reveals some of the most shocking lessons he learned from his time at Imcheck.
---Learn more about Kadans’ Oncology Clusters, where oncology biotechs grow from start-up to global player: https://bit.ly/kadans-oncology---
⭐️ ABOUT THE SPEAKERPierre has 30 years of experience in the biopharmaceutical industry, including 9 years at ImCheck and more than 3 years as EVP, Chief Strategy Officer at Theravectys. Prior to this, he also spent 10 years in senior roles in Sanofi and Baxter Healthcare.
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
Podden och tillhörande omslagsbild på den här sidan tillhör
Flot.bio. Innehållet i podden är skapat av Flot.bio och inte av,
eller tillsammans med, Poddtoppen.
